H
Helen Bright
Researcher at GlaxoSmithKline
Publications - 7
Citations - 613
Helen Bright is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Virus & Viral replication. The author has an hindex of 5, co-authored 6 publications receiving 486 citations.
Papers
More filters
Journal ArticleDOI
Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells.
Rajneesh Malhotra,Malcolm Ward,Helen Bright,Richard Priest,Martyn R. Foster,Michael Hurle,Eddie Blair,Michael I. Bird +7 more
TL;DR: Findings indicate that inhibitors of annexin II could have potential in treating RSV infection, as isolated as a potential RSV receptor on Hep2 cells.
Journal ArticleDOI
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo
Timothy P. Hickling,Helen Bright,Kevin Wing,David Gower,Steve L. Martin,Robert B. Sim,Rajneesh Malhotra +6 more
TL;DR: Intranasal administration of recombinant SP‐D to RSV‐infected mice inhibited replication of the virus in the lungs, reducing levels of lung virus by 80 %.
Journal ArticleDOI
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
Yueh Ming Loo,Patrick M. McTamney,Rosalin H. Arends,Michael E. Abram,Anastasia A. Aksyuk,Seme Diallo,Daniel J. Flores,Elizabeth J. Kelly,Kuishu Ren,Richard Roque,Kim Rosenthal,Katie Streicher,Kevin M. Tuffy,Nicholas J. Bond,Owen Cornwell,Jerome Bouquet,Li Cheng,J. Dunyak,Yue Huang,Anton I. Rosenbaum,Venkatesh Pilla Reddy,Hanne Andersen,Robert H. Carnahan,James E. Crowe,Ana I. Kuehne,Andrew S. Herbert,John M. Dye,Helen Bright,Nicole L. Kallewaard,Menelas N. Pangalos,Mark T. Esser +30 more
TL;DR: A combination of two mAbs that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2 are described and AZD7442 is projected to contribute to long-term human protection.
Journal ArticleDOI
Development of a GB Virus B Marmoset Model and Its Validation with a Novel Series of Hepatitis C Virus NS3 Protease Inhibitors
TL;DR: These studies provide the first demonstration of the in vivo efficacy of a small-molecule inhibitor for HCV in an animal model and illustrate the utility of GBV-B as a surrogate animal model system forHCV.
Journal ArticleDOI
Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells.
Timothy P. Hickling,Rajneesh Malhotra,Helen Bright,William Mcdowell,Edward D. Blair,Robert B. Sim +5 more
TL;DR: SP-A enhances the attachment of RSV and subsequent entry into host cells and the effect of SP-A on viral uptake by epithelial cells and macrophage may determine both innate and adaptive immune responses to RSV.